- Biogen Inc.
- Genzyme Corp.
- Ionis Pharmaceuticals Inc.
- Pfizer Inc.
- Abbott Laboratories Inc.
- WuXi PharmaTech Inc.
- Sirtris Pharmaceuticals Inc.
- Genentech Inc.
- Elan Corp. PLC
- Amgen Inc.
- Merck & Co. Inc.
- GlaxoSmithKline PLC
- Eli Lilly & Co.
- Daiichi Sankyo Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Piramal Enterprises Ltd.
- AstraZeneca PLC
- Forest Laboratories Inc.
- Sunovion Pharmaceuticals Inc.
- Takeda Pharmaceuticals International GMBH
- Wyeth Pharmaceuticals
- Haptogen Ltd.
- Adnexus Therapeutics Inc.
- Ambrx Inc.
- BaroFold Inc.
- OctoPlus NV
- Biolex Therapeutics Inc.
- Endo International PLC
- Allergan PLC
- Xcellerex Inc.
- Takeda Oncology
- Reliant Pharmaceuticals Inc.
- CoGenesys Inc.
- Human Genome Sciences Inc.
- Principia Pharmaceutical Corp.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Genzyme and Isis enter $1.2bn CV collaboration
- Daiichi Sankyo gets Japanese rights to Amgen's denosumab
- Takeda gets Japanese rights to 13 Amgen compounds
- Piramal agrees to develop candidates for Lilly
- Merck and Piramal work on cancer targets
- AZ and BMS enter Type II diabetes deal; BMS later sells diabetes business to AZ
- BMS, Pfizer work together on Phase III antithrombotic
- Pfizer gives BMS rights to early-stage metabolic projects
- Genentech helps Abbott develop and market two candidates
- Almirall licenses COPD agent to Forest
- Sepracor gets rights to Nycomed's ciclesonide line
- GSK adds antibody expertise through £230mm Domantis buy
- Wyeth Pharmaceuticals buys Haptogen
- BMS acquires protein drug developer Adnexus for $505mm
- Human Genome Sciences acquires Principia Pharma for $135mm
- Novartis, HGS end late-stage hepatitis C deal
- Teva moves towards biosimilars through $400mm CoGenesys buy
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.